- Our Work
- Get Involved
Amita Gupta, MD, MHS
Professor of Medicine and Public Health
Dr. Gupta is Deputy Director of the Johns Hopkins (JH) Center for Clinical Global Health Education (CCGHE), and Professor of Infectious Diseases at the JH School of Medicine, with a joint appointment in International Health at the JH Bloomberg School of Public Health.
Board certified by the American Board of Internal Medicine in infectious diseases, Dr. Gupta specializes in international public health, clinical research, and education in infectious diseases, HIV/AIDS, and tuberculosis (TB). Since 2002, her work has been focused primarily on India, where she leads several Indo-JHU research collaborations. She serves in leadership positions for the RePORT consortium for TB research, funded by the US National Institutes of Health (NIH) and the government of India, including on the RePORT International Executive Committee, as US Chair of RePORT India, and as PI of the multi-site C-TRIUMPH research consortium.
Dr. Gupta is Co-principal Investigator of the NIH-funded Baltimore-Washington-India HIV and Infectious Diseases Clinical Trials Unit (BWI-CTU), and she is an active clinical investigator in multi-country HIV/TB trials conducted by the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Trials Network (IMPAACT). Additionally, she has been awarded research grants from the NIH, CDC, and several philanthropic foundations to investigate TB in children and pregnant women, malnutrition, infection and inflammation, HIV treatment outcomes, and antibiotic resistance. Learn about CCGHE India Research Partnerships
Dr. Gupta is an author of more than 100 peer-reviewed research publications and 7 book chapters on prevention and treatment of HIV, TB, and other infectious diseases, predominantly in low- and middle-income settings. She has also mentored more than 30 junior scientists in India and the US to run research studies and submit their own scientific findings to peer-reviewed publications.
From 2000–2002, Dr. Gupta worked in the US Public Health Service for the Centers for Disease Control and Prevention (CDC), where she was engaged in global public health projects in the US, Guatemala, Vietnam, and Micronesia.
Dr. Gupta received an undergraduate degree from MIT, a Doctor of Medicine from Harvard Medical School, and a Master of Health Sciences in clinical investigation from JH Bloomberg School of Public Health. She completed her internal medicine training at San Francisco General Hospital-University of California, San Francisco, followed by a post-doctoral fellowships with the Epidemic Intelligence Service at the US Centers for Disease Control and Prevention (Foodborne and Diarrheal Diseases) and at the JHU School of Medicine (Infectious Diseases).
Research Program Building and Leadership
- 2007-present: Chair, IMPAACT P1078, A Randomized Clinical Trial to Evaluate the Safety of Immediate (antepartum-initiated) Versus Deferred Reduction in TB Incidence and Mortality Among HIV-Infected Women and Their Infants in High TB Incidence Settings
- 2008-present: Protocol Vice-Chair of ACTG 5274, Reducing Early Mortality Among Patients with Advanced HIV Disease: A Randomized Strategy Trial Comparing the Safety and Efficacy of an Individualized Patient TB Treatment Approach to a Public Health Pre-emptive TB Treatment Approach in Resource-Limited Settings (REMEMBER)
- 2008-2014: Protocol Vice-Chair ACTG 5263, A Randomized Comparison of Three Chemotherapy Regimens as an Adjunct to Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings
- 2008-2012: Co-investigator ACTG 5267, A Phase I, Safety, Tolerability, and Pharmacokinetic Interaction Study of Single-Dose TMC207 and Efavirenz in Health Volunteers
- 2008-2012: Co-investigator ACTG 5253 Sensitivity and Specificity of Mycobacterium Tuberculosis Screening and Diagnostics in HIV-Infected Individuals
- 2009-present: Protocol Vice Chair ACTG 5279, Phase III Clinical Trial of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Adults with Latent Tuberculosis Infection
- 2010: Invited by NIAID, NIH to be a part of a NIH delegation to assess scope of TB research in India. Accompanied the Deputy Director of the Division of AIDS, the Associate Director of International Health Programs, NIAID and other NIH delegates on site visits to 15 Indian institutions throughout the country
- 2010-2013: Co-investigator IMPAACT P1091 Administration of Polysaccharide or Conjugated Pneumococcal Vaccines to HIV-Infected Pregnant Women: Safety and Magnitude, Persistence, and Transplacental Transfer of Vaccine-serotype pneumococcal anti-capsular Antibodies
- 2011-2012: Selected to participate in the Johns Hopkins School of Medicine’s Office in Science and Medicine (OWISM) Leadership Program for Women Faculty
- 2012-present: Co-investigator IMPAACT P1026s, Pharmacokinetic Properties of Antiretroviral Therapy in Pregnancy
- 2012-2014: Co-investigator, IMPAACT CS4108 Protocol Team, Diagnosis of Intrathoracic Tuberculosis in HIV-infected and Uninfected Children Using Novel Sampling Strategies and the GeneXpert® MTB/RIF Assay
- 2012-present: Member, ACTG TB Transformative Science Group
- 2014-present: IMPAACT TB Scientific Committee Vice-Chair
- 2014-present: Co-investigator IMPAACT 2001 Protocol Team, PK and Safety of INH and Rifapentine in Pregnancy
- 2014-2016: US Co-chair, NIH-India Government, Regional Prospective Observational Research in Tuberculosis (RePORT)
- 2014-present: Co-chair PHOENIX ACTG A5300/IMPAACT 2003 MDR TB contact prophylaxis trial; Large multi-country trial in development
- 2015-present: Member, Union Interest Group in Maternal-Infant TB working group
- 2015-present: Member, IeDEA TB working group
- 2016-present: US Chair, TB Research Consortium, RePORT India
- 2016-present: Member, Executive Committee, RePORT International
- 2017: Selected to participate in the Johns Hopkins Leadership Development Program (LDP)
2018: Participant, Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, WHO Report generation